

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: RFA1/21 - Risk Factors for Atherosclerosis

Deadline: 09.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(111) Cholesterol</b>					303							303	283	93%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		3,74	0,12	3,3	303	CVP	3,74	0,017	8%	3,44	4,04	303	293	97%
(1) Enzyme method CHOD-PAP		3,74	0,12	3,3	303	0						303		
<b>Sample B</b>		7,92	0,29	3,6	303	CVP	7,92	0,041	8%	7,28	8,56	303	285	94%
(1) Enzyme method CHOD-PAP		7,92	0,29	3,6	303	0						303		
<b>(112) Triacylglycerols</b>					303							303	300	99%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		1,18	0,046	3,9	303	CVP	1,18	,0064	15%	1	1,36	303	300	99%
(1) Photometric enzyme (GPO-PAP)		1,18	0,045	3,8	289	0						289		
(2) Enzymatic UV method		1,14	0,029	2,5	14	0						14		
<b>Sample B</b>		2,42	0,065	2,7	303	CVP	2,42	,0091	15%	2,05	2,79	303	301	99%
(1) Photometric enzyme (GPO-PAP)		2,42	0,064	2,6	289	0						289		
(2) Enzymatic UV method		2,37	0,072	3,0	14	0						14		
<b>(113) Cholesterol HDL</b>					305							305	298	98%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		0,998	0,044	4,4	305	CVP	0,998	,0061	15%	0,848	1,15	305	298	98%
(2) Direct determination		0,998	0,044	4,4	302	0						302		
Other					3	0						3		
<b>Sample B</b>		2,17	0,093	4,3	305	<sup>3x1</sup> CVP	2,17	0,013	15%	1,84	2,5	305	301	99%
(2) Direct determination		2,17	0,093	4,3	302	0						302		
Other					3	0						3		
<b>(114) Apolipoprotein AI</b>					90							90	90	100%
— Samples and groups	[g/L]													
<b>Sample A</b>		1,15	0,063	5,5	90	CVP	1,15	0,016	21%	0,908	1,4	90	90	100%
(2) Immunoturbidimetry		1,15	0,065	5,6	82	0						82		
(3) Immunonephelometry		1,18	0,067	5,7	8	0						8		
<b>Sample B</b>		2,38	0,18	7,4	90	CVP	2,38	0,046	21%	1,88	2,88	90	90	100%
(2) Immunoturbidimetry		2,38	0,17	7,3	82	0						82		
(3) Immunonephelometry		2,28	0,18	7,8	8	0						8		
<b>(115) Apolipoprotein B</b>					105							105	103	98%
— Samples and groups	[g/L]													
<b>Sample A</b>		0,718	0,034	4,7	105	CVP	0,718	,0081	18%	0,588	0,848	105	104	99%
(2) Immunoturbidimetry		0,719	0,033	4,6	98	0						98		
(3) Immunonephelometry		0,712	0,042	5,9	7	0						7		
<b>Sample B</b>		1,49	0,087	5,9	105	CVP	1,49	0,021	18%	1,22	1,76	105	104	99%
(2) Immunoturbidimetry		1,49	0,085	5,7	98	0						98		
(3) Immunonephelometry		1,51	0,14	9,4	7	0						7		
<b>(116) Cholesterol LDL (calculation)</b>					130							130	125	96%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		2,23	0,13	5,7	130	CVP	2,23	0,027	15%	1,89	2,57	130	127	98%
(0) Not specified		2,23	0,13	5,7	130	1						130		
<b>Sample B</b>		4,71	0,25	5,3	130	CVP	4,71	0,054	15%	4	5,42	130	128	98%
(0) Not specified		4,71	0,25	5,3	130	0						130		
<b>(118) Cholesterol LDL (direct determ.)</b>					226							226	217	96%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		2,32	0,17	7,1	226	CVP	2,32	0,027	15%	1,97	2,67	226	220	97%
(0) Not specified		2,32	0,17	7,1	226	0						226		
<b>Sample B</b>		4,92	0,40	8,2	226	CVP	4,92	0,066	15%	4,18	5,66	226	219	97%
(0) Not specified		4,92	0,40	8,2	226	0						226		
<b>(117) Lipoprotein (a) [g/L]</b>					33							33	33	100%
— Samples and groups	[g/L]													
<b>Sample A</b>		0,179	0,018	10	33	CVP	0,179	,0076	32%	0,121	0,237	33	33	100%
(2) Immunoturbidimetry		0,181	0,015	8,3	29	0						29		
Other					4	0						4		
<b>Sample B</b>		0,390	0,023	6,0	33	<sup>1x0,3x3</sup> CVP	0,39	,0100	32%	0,265	0,515	33	33	100%
(2) Immunoturbidimetry		0,392	0,021	5,3	29	0						29		
Other					4	0						4		

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: RFA1/21 - Risk Factors for Atherosclerosis

Deadline: 09.04.2021

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(119) Lipoprotein (a) [nmol/L]</b>	[nmol/L]				29								29	27	93%
----- Samples and groups -----															
<b>Sample A</b>		31,8	3,0	9,5	29		CVP	31,8	1,4	20%	25,4	38,2	29	27	93%
(2) Immunoturbidimetry		31,8	2,8	8,9	27	0							27		
Other					2	0							2		
-----							1x 0, 1x 3								
<b>Sample B</b>		78,5	4,4	5,6	29		CVP	78,5	2,0	20%	62,8	94,2	29	28	97%
(2) Immunoturbidimetry		78,0	4,0	5,1	27	0							27		
Other					2	0							2		
-----							1x 0, 1x 3								

st\_kn\_p

End of report

Printed: 20.04.2021